Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rare severe constrictive pericarditis complication in Erdheim-Chester disease: A case report and literature review.
Miyazaki T, Kamimura D, Wakamatsu M, Konishi M, Matsumura A, Teshigawara H, Teranaka H, Koyama S, Takahashi H, Kunimoto H, Enaka M, Hagihara M, Matsumoto K, Yamazaki E, Nakajima H. Miyazaki T, et al. Among authors: yamazaki e. J Clin Exp Hematop. 2024 Sep 28;64(3):232-236. doi: 10.3960/jslrt.24006. Epub 2024 Jul 31. J Clin Exp Hematop. 2024. PMID: 39085132 Free PMC article. Review.
Successful Treatment of Unresectable BRCA1 L63*-Mutated Basal Cell Carcinoma Invading the Parietal Bone with Cisplatin and Fluorouracil: A Case Report.
Yoshida-Akai S, Fujimura T, Amagai R, Kambayashi Y, Hashimoto A, Terui H, Oka K, Watanabe-Takahashi M, Yamazaki E, Ohuchi K, Asano Y. Yoshida-Akai S, et al. Among authors: yamazaki e. Case Rep Oncol. 2024 Sep 20;17(1):1050-1054. doi: 10.1159/000541160. eCollection 2024 Jan-Dec. Case Rep Oncol. 2024. PMID: 39474537 Free PMC article.
Decreased serum levels of IL-4 correlate with the efficacy of the PAI-1 inhibitor TM5614 in patients with malignant melanoma refractory to anti-PD-1 antibodies: post hoc study of TM5614-MM trial.
Yamazaki E, Fujimura T, Takahashi-Watanabe M, Tada S, Kitayama C, Amagai R, Kambayashi Y, Watanabe M, Maekawa M, Mano N, Asano Y. Yamazaki E, et al. Br J Dermatol. 2024 Aug 31:ljae343. doi: 10.1093/bjd/ljae343. Online ahead of print. Br J Dermatol. 2024. PMID: 39215562 No abstract available.
A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial.
Fujimura T, Yoshino K, Kato H, Fukushima S, Ishizuki S, Otsuka A, Matsushita S, Amagai R, Muto Y, Yamazaki E, Kambayashi Y, Yahata T, Miyata T, Fujisawa Y, Asano Y. Fujimura T, et al. Among authors: yamazaki e. Br J Dermatol. 2024 Oct 17;191(5):691-697. doi: 10.1093/bjd/ljae231. Br J Dermatol. 2024. PMID: 38833158 Clinical Trial.
275 results